An insight into the therapeutic potential of quinazoline derivatives as anticancer agents

Abstract

Cancer is one of the major causes of worldwide human mortality. A wide range of cytotoxic drugs are available on the market, and several compounds are in different phases of clinical trials. Many studies suggest that these cytotoxic molecules are also associated with different types of adverse side effects; therefore researchers around the globe are involved in the development of more efficient and safer anticancer drugs. In recent years, quinazoline and its derivatives have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors. The aim of this article is to comprehensively review and highlight the recent developments concerning the anticancer activity of quinazoline derivatives as well as offer perspectives on the development of novel quinazoline derivatives as anticancer agents in the near future.

2,4-Substituted Quinazoline as Jak2 Inhibitor: Docking and Molecular Dynamics Study

“…The heterocycles are widely known as bioactive molecules and are considered as an important synthetic target for the development of novel therapeutic agents [11][12]. Quinazoline is one of the heterocycles used as a basic framework that produces biologically active compounds and drug molecules [13].…”

Structural characterizations, spectroscopic, electrochemical properties, and antibacterial activities of copper (II) and cobalt (II) complexes containing imidazole ring

“…Their possible applications in various fields, such as nanocatalyst, nonlinear optical activity, molecular sensors, magnetic switches, corrosion inhibition and anti‐cancer and anti‐viral activities . Quinazoline ring system is a parent structure of N‐heterocyclic compounds that have many alkaloids is a widely recognized moiety in inorganic syntheses and in numerous bioactive molecules, such as antiasthmatic, anti‐HIV‐1, antiviral and antimalarial . In addition, quinoline and its derivatives exhibit high affinity to metal ions, they can form different types of coordination compounds owing to several electron‐rich donor centers with unusual structural and chemical properties .…”

Copper-catalyzed domino sequences: a new route to pyrido-fused quinazolinones from 2′-haloacetophenones and 2-aminopyridines

“…14,15 Upon base-mediated hydrolysis, G was generated, and the consequent intramolecular addition cyclization occurred to form H. In the next step, decarboxylation and oxidation occurred to form the desired product (3) in the presence of copper catalyst and oxygen. Certainly, the conversion of F to the quinazolinone was demonstrated by Liu et al 16 For Path II, the hydration of (7) and subsequent 1,2-hydride shi led to the formation of anionic intermediate J. Consequently, decarboxylation occurred to produce (5), and (5) was oxidized to (6) in the presence of copper catalyst and oxygen. 17,21 Intermediate K was formed via an Ullmann-Goldberg coupling, and the consequent amidation cyclization occurred to furnish the desired quinazolinone (3).…”

“…[1][2][3] Quinazolinone derivatives have emerged as a family of privileged structural motifs with a broad spectrum of pharmacological and biological activities. [4][5][6][7] Fused quinazolinones, members of this nitrogen-containing heterocycle family, have particularly gained remarkable interest from the pharmaceutical and medicinal industries. 8,9 Several efforts have been dedicated to the synthesis of pyrido-fused quinazolinones due to their pharmaceutical value.…”

“…Furthermore, 2 0 -iodoacetophenone demonstrated greater reactivity over the 2 0 -bromoacetophenone, affording the corresponding products in higher yields (Entry 9, 10, 11, 12, Table 3). Noticeably, this method can be applicable to the concise construction of 12H-benzo [4,5]thiazolo [2,3-b]quinazolin-12-ones. By utilizing 2 0 -bromoacetophenone and 2 0 -iodoacetophenone in the reaction with benzo[d]thiazol-2-amine under standard reaction conditions, the corresponding products were achieved in 57% and 63% yields, respectively (Entry 8, 11, Table 3).…”